Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: A network meta-analysis

Gastrointestinal Endoscopy

Volumn 81, Issue 3, 2015, Pages 700-709.e3

  Elmunzer, B Joseph ^a   Singal, Amit G ^b   Sussman, Jeremy B ^a,c   Deshpande, Amar R ^d   Sussman, Daniel A ^d   Conte, Marisa L ^c   Dwamena, Ben A ^a   Rogers, Mary A M ^c   Schoenfeld, Philip S ^a   Inadomi, John M ^e   Saini, Sameer D ^a   Waljee, Akbar K ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CLINICAL EVALUATION; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; SENSITIVITY ANALYSIS; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; BAYES THEOREM; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; EARLY DIAGNOSIS; MORTALITY; OCCULT BLOOD; PROCEDURES;

BAYES THEOREM; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; EARLY DETECTION OF CANCER; HUMANS; OCCULT BLOOD; SIGMOIDOSCOPY;

EID: 84923285842     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2014.10.033     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi- Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95.
4. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37.
5. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
6. Colonoscopy versus fecal immunochemical test in reducing mortality from colorectal cancer (CONFIRM). Clinicaltrials.gov identifier: NCT01239082. Study in progress.
7. Hoff G, Dominitz JA. Contrasting US and European approaches to colorectal cancer screening: Which is best? Gut 2010;59:407-14.
8. National Committee on Colorectal Cancer Screening. Recommendations for population-based colorectal cancer screening. Ottawa: Health Canada; 2002. Available at: www.hc-sc.gc.ca/pphb-dgspsp/publicat/ncccs-cndcc/index.html. Accessed June 15, 2013.
9. Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen 2006;(13 suppl 1):S6-7.
10. Shapiro JA, Klabunde CN, Thompson TD, et al. Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2012;21: 895-904.
11. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-50.
12. Use of colorectal cancer tests - United States, 2002, 2004, and 2006. MMWR Morb Mortal Wkly Rep 2008;57:253-8.
13. Steinwachs D, Allen JD, Barlow WE, et al. National Institutes of Health state-of-the-science conference statement: enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010;152:663-7.
14. Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group, National Health Expenditure Data, January 2012. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpend Data/index.html. Accessed March 2013.
15. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-69.
16. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008;27:697-712.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
19. Schoenfeld P, Cook D, Hamilton F, et al. An evidence-based approach to gastroenterology therapy. Evidence-Based Gastroenterology Steering Group. Gastroenterology 1998;114:1318-25.
20. Wells GA, Shea B, O'Connell D, et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed January 14, 2013.
21. GeMTC GUI statistical package. Available at: http://drugis.org/gemtc. Accessed March 3, 2013.
22. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369: 1095-105.
23. Myers RE, Balshem AM, Wolf TA, et al. Adherence to continuous screening for colorectal neoplasia. Med Care 1993;31:508-19.
24. Engelman KK, Ellerbeck EF, Ahluwalia JS, et al. Fecal occult blood test use by Kansas Medicare beneficiaries. Prev Med 2001;33:622-6.
25. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med 2012;172:575-82.
26. Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011;154:22-30.
27. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8.
28. Singh H, Nugent Z, Demers AA, et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 2010;139:1128-37.
29. Hiraoka S, Kato J, Tatsukawa M, et al. Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology 2006;131:379-89.
30. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001;93:1307-13.
31. Cohen LB. Split dosing of bowel preparations for colonoscopy: an analysis of its efficacy, safety, and tolerability. Gastrointest Endosc 2010;72: 406-12.
32. Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology 2013;144:74-80.e1.
33. Coe SG, Crook JE, Diehl NN, et al. An endoscopic quality improvement program improves detection of colorectal adenomas. Am J Gastroenterol 2013;108:219-26; quiz 27.
34. Pohl J, Schneider A, Vogell H, et al. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. Gut 2011;60: 485-90.
35. Gross SA, Buchner AM, Crook JE, et al. A comparison of high definition-image enhanced colonoscopy and standard white-light colonoscopy for colorectal polyp detection. Endoscopy 2011;43:1045-51.
36. Liu Z, Miller SJ, Joshi BP, et al. In vivo targeting of colonic dysplasia on fluorescence endoscopy with near-infrared octapeptide. Gut 2013;62: 395-403.
37. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial - SCORE. J Natl Cancer Inst 2011;103: 1310-22.
38. Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol 2007;166:1203-9.
39. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8: e1001026.
40. Hernan MA, Hernandez-Diaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med 2013;159:560-2.
41. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334: 155-9.
42. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370: 1287-97.
43. Kaminski MF, Bretthauer M, Zauber AG, et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012;44:695-702.
44. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-84.
45. Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test?A comparison of costs, effectiveness, and compliance. Am J Med 2001;111:593-601.